Role of galectin 3 and epicardial fat thickness in the development of atrial fibrillation in patients with metabolic syndrome
Objective. To evaluate the epicardial fat thickness (EFT) in patients with metabolic syndrome (MS), including paroxysmal and persistent atrial fibrillation (AF). To relate EFT to the fibroid heart marker, i.e. galectin 3. Materials and methods. We examined 100 patients with MS (50 with AF), and 50 h...
Main Authors: | V. A. Ionin, O. V. Listopad, S. E. Nifontov, E. I. Baranova, A. V. Soboleva, E. V. Shlyakhto |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Academician I.P. Pavlov First St. Petersburg State Medical University
2015-03-01
|
Series: | Učenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta im. Akad. I.P. Pavlova |
Subjects: | |
Online Access: | https://www.sci-notes.ru/jour/article/view/110 |
Similar Items
-
UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION
by: E. A. Protasova, et al.
Published: (2015-12-01) -
Clinical significance of TNF-a assessment as inflammation marker in paroxysmal atrial fibrillation
by: E M Esedov, et al.
Published: (2014-12-01) -
PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-09-01) -
GALECTIN 3 AND ALDOSTERONE IN PATIENTS WITH ATRIAL FIBRILLATION AND METABOLIC SYNDROME
by: V. A. lonin, et al.
Published: (2015-04-01) -
MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION
by: E. A. Belikov, et al.
Published: (2015-09-01)